The ability of cancer cells to detach from the primary site and metastasize is the main cause of cancer- related death among all cancer types. Epithelial-to-mesenchymal transition (EMT) is the first event of the metastatic cascade, resulting in the loss of cell–cell adhesion and the acquisition of motile and stem-like phenotypes. A critical modulator of EMT in cancer cells is the stromal tumor microenvironment (TME), which can promote the acquisition of a mesenchymal phenotype through direct interaction with cancer cells or changes to the broader microenvironment. In this review, we will explore the role of stromal cells in modulating cancer cell EMT, with particular emphasis on the function of mesenchymal stromal/stem cells (MSCs) through the activation of EMT-inducing pathways, extra cellular matrix (ECM) remodeling, immune cell alteration, and metabolic rewiring.
The fundamental steps in high-grade serous ovarian cancer (HGSOC) initiation are unclear, presenting critical barriers to the prevention and early detection of this deadly disease. Current models propose that fallopian tube epithelial (FTE) cells transform into serous tubal intraepithelial carcinoma (STIC) precursor lesions and subsequently into HGSOC. In this study, we report that an epigenetically altered mesenchymal stem cell niche, termed high-risk mesenchymal stromal/stem cell (hrMSC), exists prior to STIC lesion formation. hrMSCs are enriched in STIC stroma and contribute to a stromal “field effect” extending beyond the borders of the STIC lesion. hrMSCs promote DNA damage in FTE cells while also fostering FTE cell survival. hrMSCs induce malignant transformation of the FTE, resulting in metastatic cancer in vivo, indicating that hrMSCs promote cancer initiation. hrMSCs are significantly enriched in BRCA1/2 mutation carriers and increase with age. Combined, these findings indicate that hrMSCs can incite ovarian cancer initiation and have important implications for ovarian cancer detection and prevention. Significance: This work demonstrates a critical role of fallopian tube stromal cells in HGSOC initiation with implications for the pathophysiology of HGSOC formation and the development of prevention and early detection strategies critically needed in this disease. Additionally, the identification of stromal-mediated epithelial transformation has broad implications for understanding pan-cancer initiation. See related commentary by Recouvreux and Orsulic, p. 1093
Extramammary Paget’s disease (EMPD) is a rare malignancy of the skin arising in apocrine gland-rich areas, most commonly the vulva, scrotum, and perianal region. Often misdiagnosed due to resemblance to benign dermatologic conditions, EMPD presents diagnostic and therapeutic challenges. While localized disease usually has a favorable prognosis after surgery, metastatic EMPD is rare, with poor outcomes and limited options. Recent molecular profiling has identified human epidermal growth factor receptor 2 (HER2) overexpression as a potential therapeutic target. We present a clinical series of HER2-positive EMPD treated with targeted therapies and review the literature to assess their role in disease control and outcomes. We report two cases of metastatic HER2-amplified vulvar EMPD treated with HER2-directed agents, including trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd), and integrate our findings into a narrative review of reported cases. Both patients achieved clinical benefit from HER2-targeted therapy with disease control across sequential regimens. We describe one of the first documented real-world cases of vulvar EMPD treated with T-DXd, showing a meaningful clinical response. HER2-positive metastatic vulvar EMPD may respond to targeted therapy, and T-DXd appears promising for disease control. Molecular HER2 testing should be incorporated into the diagnostic workup to guide therapy selection in this rare malignancy.
A ictiose arlequim possui uma prevalência de 1/100.000 nascimentos e é frequente o óbito ocorrer no período neonatal. Objetivo: descrever um caso em que o tratamento adequado permitiu a sobrevida da paciente. Descrição do caso: Recém-nascido (RN) do sexo feminino com 2665g, nasceu com placas hiperceratósicas e fissuras difusas pelo corpo, ectrópio bilateral com oclusão palpebral, eclábio e pés e mãos fletidos características de Ictiose congênita do tipo arlequim. O acitretin foi iniciado aos 7 dias de vida associado ao tratamento suportivo, evitando o óbito neonatal. Comentários: Atribui-se a sobrevida da paciente à intervenção com acitretin oral precoce e os cuidados intensivos neonatais.
Background/objectives: Understanding the immune landscape in cervical cancer is critical to the development of improved therapeutics. This study investigated the immune microenvironment in early-stage cervical cancer with a focus on B and T cell immune aggregates, i.e., lymphoid aggregates (LAs) and tertiary lymphoid structures (TLSs). Methods: Using multispectral imaging, we interrogated a cohort of patients with clinical stage I squamous or adenocarcinoma of the cervix with a focus on T and B cell spatial location and organization. Despite early-stage disease, recurrence was common at 37%, highlighting the need to identify patients at high risk for recurrence. Results: We demonstrated that high CD8+ T cell infiltration correlated significantly with improved overall survival (OS), particularly in patients with adenocarcinoma histology. CD8+ T cells colocalized with B cells, suggesting the formation of a more sophisticated cellular neighborhood, i.e., TLS, which has prognostic benefit in other solid tumors. CXCL13, a chemokine associated with TLS formation, correlated with improved recurrence-free survival. The combination of high CXCL13 and lymphoid structures correlated with improved OS. However, most immune structures in cervical cancer were lymphoid aggregates (LAs) that lack features of more developed TLS, such as high endothelial venules (HEVs) and germinal centers (GCs), highlighting a lack of full immune activation in this microenvironment. Validation in The Cancer Genome Atlas (TCGA) cohort illustrated similar trends in survival. Conclusions: Collectively, this work demonstrates the prognostic significance of immune infiltration and eventual TLS induction in early cervical cancer and presents potential future therapeutic targets.
Purpose: Tolerability and completion of pembrolizumab with neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) varies across age groups. We evaluated age-related patterns in immune-related adverse events (irAEs), pembrolizumab exposure, and clinical outcomes in TNBC patients treated with the KEYNOTE-522 regimen.Methods: We retrospectively analyzed TNBC patients treated with neoadjuvant ± adjuvant pembrolizumab from 2020–2025 at a multicenter healthcare network. Patients were stratified by median age (53 years), with a prespecified sensitivity analysis at 65 years. We compared irAE incidence and severity, treatment completion, pathologic complete response (pCR), event-free survival, and overall survival (OS) using Kaplan–Meier analysis and univariable Cox regression.Results: Among 125 patients, 36.8% developed an irAE, and 15.2% experienced grade ≥3 events. Patients <53 years experienced more irAEs (51% vs. 31%; p = 0.03), developed toxicity earlier (mean 5.7 vs. 7.2 cycles), and required more corticosteroid therapy (36% vs. 18%; p = 0.04). This association was consistent in the sensitivity analysis (odds ratio 3.63, 95% confidence interval [CI] 1.43–9.06, p = 0.006). Despite reduced pembrolizumab exposure, pCR was similar across age groups (72% vs. 73%; p = 0.8). Completion of adjuvant pembrolizumab was associated with improved OS overall (hazard ratio 0.17, 95% CI 0.04–0.75), with a trend toward older patients benefiting more.Conclusion: Younger patients experienced more frequent and earlier irAEs leading to treatment discontinuation yet achieved comparable pCR rates. Older patients were more likely to complete the full regimen with a trend toward improved survival with treatment completion. Age-adapted immunotherapy strategies in early-stage TNBC should be explored.